Morgan Stanley Boosts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $250.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective increased by Morgan Stanley from $164.00 to $250.00 in a report released on Tuesday, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the company. StockNews.com raised Alnylam Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, April 29th. Needham & Company LLC lifted their price target on Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the stock a buy rating in a research report on Monday. Chardan Capital reaffirmed a buy rating and issued a $225.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Canaccord Genuity Group reissued a buy rating and set a $283.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, June 21st. Finally, William Blair reissued an outperform rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Eight analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $245.14.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $247.00 on Tuesday. The stock’s 50 day simple moving average is $157.89 and its 200 day simple moving average is $164.23. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $252.87. The company has a market capitalization of $31.24 billion, a price-to-earnings ratio of -92.16 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The business’s quarterly revenue was up 54.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.40) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals will post -3.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Jeffrey V. Poulton sold 1,605 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $231.00, for a total transaction of $370,755.00. Following the completion of the sale, the chief financial officer now owns 28,892 shares in the company, valued at $6,674,052. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the sale, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,357 shares of company stock valued at $13,436,711. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $390,438,000. Capital International Investors increased its holdings in Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after purchasing an additional 488,814 shares during the last quarter. Wellington Management Group LLP increased its holdings in Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after purchasing an additional 364,021 shares during the last quarter. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the last quarter. Finally, Capital Research Global Investors increased its holdings in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.